 Cassava Sciences Inc NASDAQ: SAVA has initiated a second Phase 3 study of simufilam in patients with Alzheimers disease. The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients. 